The efficacy of apatinib has been confirmed in the treatment of solid tumors, including non-
small-cell lung cancer (NSCLC). However, the direct functional mechanisms of tumor …

The emergence of secondary resistance is the main failure cause of epidermal growth factor
receptor-tyrosine kinase inhibitors (EGFR-TKIs) as a targeted therapy for non-small cell lung …

Chemotherapy is one of the main treatment approaches for lung cancer. However, few drugs
can be used in the post-first-line treatment of lung cancer. Apatinib is a small molecule …

Simple Summary In the Asian population, 50–60% of non-small cell lung cancer (NSCLC)
patients carry the epidermal growth factor receptor (EGFR) mutation. Although treatment with …

Overexpression of insulin growth factor 1 receptor (IGF-1R) and its ligand, insulin growth
factor 1 (IGF-1), is related to treatment resistance and worse prognosis in many types of …

Background Recently, a variety of clinical trials have shown that apatinib, a small-molecule
anti-angiogenic drug, exerts promising inhibitory effects on multiple solid tumors, including …

Background Non-small cell lung cancer (NSCLC) has a poor prognosis and is the most
common cause of cancer-related deaths worldwide. Aminoacylase 1 (ACY1) plays a …

Chemotherapy is the standard treatment of in advanced lung adenocarcinoma patients
without driver mutation. However, few drugs could be selected when diseases progressed …

OBJECTIVE: To observe the reversal effect of apatinib on the resistance to cisplatin (DDP) of
A549/cisplatin (A549/DDP) cells and its relevant mechanism. MATERIALS AND METHODS …

Background/Aim: Multidrug resistance (MDR) is often associated with overexpression of P-
glycoprotein (ABCB1) in cancer cells. Apatinib is a novel Vascular endothelial growth factor …